CNS Drugs

, Volume 25, Issue 10, pp 829–845 | Cite as

Dosing and Switching Strategies for Paliperidone Palmitate

Based on Population Pharmacokinetic Modelling and Clinical Trial Data
  • Mahesh N. SamtaniEmail author
  • Srihari Gopal
  • Cristiana Gassmann-Mayer
  • Larry Alphs
  • Joseph M. Palumbo
Review Article


Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic recently approved by the US FDA and European Medicines Agency for use in patients with schizophrenia. This article reviews the recommended dosing regimens for initiation and maintenance treatment with paliperidone palmitate in adult patients with schizophrenia. We also address issues of switching to paliperidone palmitate from other antipsychotics, managing missed doses and dosing in special patient populations.

The dosing recommendations that were approved by the FDA and other regulatory agencies around the world are based on the results of population pharmacokinetic (PK) simulations and data from clinical trials that are presented in this review. A one-compartment disposition model with zero/ first-order absorption best described the PK of paliperidone palmitate. Population PK models for extended-release paliperidone and long-acting risperidone were also developed and we report the results from these models. The PK profiles for 5000 patients were simulated after paliperidone palmitate injections. The population median and 90% prediction intervals of the simulated plasma concentration versus time profiles after multiple doses are graphically displayed in this review. Based on the data from model-based PK simulations, the approved recommended initiation regimen for paliperidone palmitate is 150 mg equivalent (mg eq.) paliperidone (paliperidone palmitate 234 mg) on day 1 followed by 100 mg eq. paliperidone (paliperidone palmitate 156 mg) on day 8, each administered into the deltoid muscle, using a 1-inch 23-gauge needle in those weighing <90 kg and a 1.5-inch 22-gauge needle in those weighing ≥90 kg. No oral supplementation is required. Monthly maintenance dosing is in the range of 25–150 mg eq. paliperidone (paliperidone palmitate 39–234 mg; recommended dose of 75 mg eq. paliperidone [paliperidone palmitate 117 mg]) injected into the deltoid (needle size is weight adjusted) or gluteal (using a 1.5-inch 22-gauge needle) muscle. The day 8 dose may be administered ±2 days and monthly doses ±7 days, without a clinically significant impact on plasma concentrations. The re-initiation schedule in patients whose last maintenance dose was >6 weeks previously is dependent upon the duration of time since the last paliperidone palmitate injection.

In patients with mild renal impairment (creatinine clearance [CLCR]: 50–80 mL/min), dosage should be adjusted. No dose adjustment is required in patients with mild or moderate hepatic impairment; no data currently exist regarding severe hepatic impairment. Elderly patients with normal renal function should receive the same dosage as younger adult patients with normal renal function. In the event of an age-related decline in CLCR, dosage should be adjusted accordingly. Paliperidone palmitate can be initiated the day after discontinuing previous oral antipsychotic treatment. In patients switching from other LAIs (including long-acting risperidone), paliperidone palmitate dosing should be initiated at the time of what would have been the next scheduled injection of the previous LAI, and continued monthly thereafter.

In summary, following initiation dosing, paliperidone palmitate is administered on a monthly basis. It is the first of the second-generation anti-psychotics to be available and approved with this dosing regimen. Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic.


Risperidone Paliperidone Paliperidone Palmitate Oral Antipsychotic Initiation Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to thank Frances Gambling, Medicus International, for her editorial assistance (collating data, editing and proof reading) in the development of this manuscript. Editorial assistance was supported by funding from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

S.G., M.S., C.G.-M. and J.P. have disclosed that they are employees of Johnson & Johnson. S.G., M.S. and C.G.-M. have disclosed that they also own Johnson & Johnson stocks. L.A. has disclosed that he is an employee of Ortho-McNeil Janssen Scientific Affairs, LLC, a subsidiary of Johnson & Johnson.

Supplementary material

40263_2012_25100829_MOESM1_ESM.pdf (1.4 mb)
Supplementary material, approximately 1466 KB.


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington (VA): American Psychiatric Publishing, Inc., 1994Google Scholar
  2. 2.
    Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003 Nov; 64(11): 1308–15PubMedCrossRefGoogle Scholar
  3. 3.
    Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995 Aug; 346(8973): 477–81PubMedCrossRefGoogle Scholar
  4. 4.
    Invega Sustenna™: US prescribing information [online]. Available from URL: [Accessed 2009 Sep]
  5. 5.
    Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001 Nov; 62(11): 855–9PubMedCrossRefGoogle Scholar
  6. 6.
    Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005 Jul; 20(4): 213–21PubMedCrossRefGoogle Scholar
  7. 7.
    Lasser R, Bossie C, Gharabawi G, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004 Jun; 19: 219–25PubMedCrossRefGoogle Scholar
  8. 8.
    Gopal S, Gassmann-Mayer C, Palumbo J, et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010 Feb; 26(2): 377–87PubMedCrossRefGoogle Scholar
  9. 9.
    Gopal S, Lindenmayer J, Hough D, et al. Safety and tolerability profiles of paliperidone palmitate injected into either the deltoid or gluteus muscle in patients with schizophrenia. 60th Annual Meeting of the Institute of Psychiatric Services; 2008 May 3–8; Chicago (IL)Google Scholar
  10. 10.
    Nasrallah H, Gopal S, Gassman-Mayer C, et al. Efficacy and safety of three doses of paliperidone palmitate, an investigational long-acting injectable antipsychotic, in schizophrenia [poster no. 125]. 60th Annual Meeting of the Institute of Psychiatric Services; 2008 May 3–8; Chicago (IL)Google Scholar
  11. 11.
    Kramer M, Litman R, Lane R, et al. Efficacy and tolerability of paliperidone palmitate: 9-week, placebo-controlled study in schizophrenia patients. Biol Psychiatry 2008; 63: 1S-319SCrossRefGoogle Scholar
  12. 12.
    Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009 Aug; 33(6): 1022–31PubMedCrossRefGoogle Scholar
  13. 13.
    Pandina G, Lindenmayer J, Lull J, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess efficacy and safety of paliperidone palmitate in adult subjects with schizophrenia [poster no. 31]. Annual Meeting of the International Congress of Schizophrenia Research; 2009 Mar 27–28; San Diego (CA)Google Scholar
  14. 14.
    Samtani M, Gopal S, Kern Sliwa J, et al. Paliperidone palmitate dosing in special populations: guidance based on pharmacokinetic modeling and simulation [poster no. K4]. American Conference on Pharmacometrics; 2009 Oct 4–7; Mashantucket (CT)Google Scholar
  15. 15.
    Samtani M, Gopal S, Kern Sliwa J, et al. Management of missed paliperidone palmitate doses based on pharmacokinetic modeling and simulation [poster no. II-62]. New Clinical Drug Evaluation Unit Annual Meeting; 2009 Jun 29–Jul 2; Hollywood (FL)Google Scholar
  16. 16.
    Samtani M, Gopal S, Kern Sliwa J, et al. Switching to paliperidone palmitate from other antipsychotics: guidance based on pharmacokinetic modeling and simulations [poster no. I-68]. New Clinical Drug Evaluation Unit Annual Meeting; 2009 Jun 29–Jul 2; Hollywood (FL)Google Scholar
  17. 17.
    Samtani M, Haskins J, Alphs L, et al. Maintenance dosing of once-monthly (4-weekly) paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on population simulations [poster no. 21]. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2009 Apr 19–20; Jacksonville (FL)Google Scholar
  18. 18.
    Samtani M, Kern Sliwa J, Haskins J, et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation [poster no. 19]. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2009 Apr 19–20; Jacksonville (FL)Google Scholar
  19. 19.
    Samtani M, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly long-acting formulation of atypical antipsychotic. Clin Pharmacokinet 2009 Sep; 48(9): 585–600PubMedCrossRefGoogle Scholar
  20. 20.
    Cirincione B, Redman M, Fiedler-Kelley J, et al. Population pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophrenia [poster no. PI-21]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2007 Mar 21–24; Anaheim (CA)Google Scholar
  21. 21.
    Samtani M, Gopal S, Kern Sliwa J, et al. Switching to paliperidone palmitate from other depot antipsychotics: guidance based on pharmacokinetic simulations [abstract no. 1839]. Annual Meeting of the Population Approach Group in Europe; 2010 Jun 9–11; BerlinGoogle Scholar
  22. 22.
    Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label single-dose studies [abstract no. PIII-57]. Clin Pharm Ther 2006; 79(2): 74CrossRefGoogle Scholar
  23. 23.
    Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993 Feb; 33(4): 227–35PubMedCrossRefGoogle Scholar
  24. 24.
    Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995 Feb; 152(2): 173–8PubMedGoogle Scholar
  25. 25.
    Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996 Jul; 153(7): 948–50PubMedGoogle Scholar
  26. 26.
    Cleton A, Rossenu S, Crauwels H, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic, following administration in the deltoid or gluteal muscles [poster no. PI-74]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2008 Apr 2–5; Orlando (FL)Google Scholar
  27. 27.
    Cleton A, Rossenu S, Hough D, et al. Evaluation of the pharmacokinetic profile of deltoid versus gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia [poster no. PI-75]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2008 Apr 2–5; Orlando (FL)Google Scholar
  28. 28.
    Invega™: US prescribing information [online]. Available from URL: [Accessed 2011 Jul 21]
  29. 29.
    Fleischhacker W, Gopal S, Samtani M, et al. Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: results of two randomized double-blind studies and population pharmacokinetic simulations [poster no. 21]. Annual Meeting of American College of Neuropsychopharmcologists; 2008 Dec 7–11; Scottsdale (AZ)Google Scholar
  30. 30.
    Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 11: 12–25Google Scholar
  31. 31.
    Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46(5): 359–88PubMedCrossRefGoogle Scholar
  32. 32.
    Vermeir M, Boom S, Naessens I, et al. Absorption, metabolism and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008 Apr; 36(4): 769–79PubMedCrossRefGoogle Scholar
  33. 33.
    Wikipidea, The Free Encyclopedia. Typical antipsychotic [online]. Available from URL: http://enwikipediaorg/wiki/Typical_antipsychotic [Accessed 2009 Aug 27]
  34. 34.
    Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63(5): 493–512PubMedCrossRefGoogle Scholar
  35. 35.
    Levron JC, Ropert R. Clinical pharmacokinetics of haloperidol decanoate: comparison with other prolonged-action neuroleptics. L’Encephale 1987 Mar–Apr; 13(2): 83–7PubMedGoogle Scholar
  36. 36.
    Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998 Feb; 8(1): 55–66PubMedCrossRefGoogle Scholar
  37. 37.
    Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophrenia. Int J Neuropsychopharmacol 2005 Mar; 8(1): 27–36PubMedCrossRefGoogle Scholar
  38. 38.
    Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009 Oct; 47(10): 606–16PubMedGoogle Scholar
  39. 39.
    Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985 Jul–Aug; 10(4): 315–33PubMedCrossRefGoogle Scholar
  40. 40.
    Ereshefsky L, Saklad SR, Tran-Johnson T, et al. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacol Bull 1990; 26(1): 108–14PubMedGoogle Scholar
  41. 41.
    Ereshefsky L, Toney G, Saklad SR, et al. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry 1993 Dec; 44(12): 1155–61PubMedGoogle Scholar
  42. 42.
    Wei FC, Jann MW, Lin HN, et al. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry 1996 Jul; 57(7): 298–302PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Mahesh N. Samtani
    • 1
    Email author
  • Srihari Gopal
    • 2
  • Cristiana Gassmann-Mayer
    • 2
  • Larry Alphs
    • 3
  • Joseph M. Palumbo
    • 2
  1. 1.Advanced PK-PD Modeling & Simulation DepartmentJohnson & Johnson Pharmaceutical Research & Development, L.L.C.RaritanUSA
  2. 2.Johnson & Johnson Pharmaceutical Research & Development, L.L.C.TitusvilleUSA
  3. 3.Ortho-McNeil Janssen Scientific Affairs, L.L.C.TitusvilleUSA

Personalised recommendations